The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
Open accessAbstract
PURPOSE: Positron emission tomography (PET) with choline tracers has found widespread use for the diagnosis of prostate cancer (PC). However, choline metabolism is not increased in a considerable number of cases, whereas prostate-specific membrane antigen (PSMA) is overexpressed in most PCs. Therefore, a (68)Ga-labelled PSMA ligand could be superior to choline tracers by obtaining a high contrast. The aim of this study was to compare such a novel tracer with standard choline-based PET/CT. METHODS: Thirty-seven patients with biochemical relapse of PC [mean prostate-specific antigen (PSA) 11.1 ± 24.1 ng/ml, range 0.01-116] were retrospectively analysed after (18)F-fluoromethylcholine and (68)Ga-PSMA PET/CT within a time window of 30 days. Radiotracer uptake that was visually considered as PC was semi-quantitatively analysed by measuring the maximum standardized uptake values (SUVmax) of the scans acquired 1 h after injection of (68)Ga-PSMA complex solution (median 132 MBq, range 59-263 MBq) and (18)F-fluoromethylcholine (median 237 MBq, range 114-374 MBq), respectively. In addition, tumour to background ratios were calculated. RESULTS: A total of 78 lesions characteristic for PC were detected in 32 patients using (68)Ga-PSMA PET/CT and 56 lesions were detected in 26 patients using choline PET/CT. The higher detection rate in (68)Ga-PSMA PET/CT was statistically significant (p=0.04). In five patients no lesion was found with both methods. All lesions detected by (18)F-fluoromethylcholine PET/CT were also seen by (68)Ga-PSMA PET/CT. In (68)Ga-PSMA PET/CT SUVmax was clearly (>10 %) higher in 62 of 78 lesions (79.1 %) and the tumour to background ratio was clearly (>10 %) higher in 74 of 78 lesions (94.9 %) when compared to (18)F-fluoromethylcholine PET/CT. CONCLUSION: (68)Ga-PSMA PET/CT can detect lesions characteristic for PC with improved contrast when compared to standard (18)F-fluoromethylcholine PET/CT, especially at low PSA levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Afshar-Oromieh, A., Malcher, A., Eder, M., Eisenhut, M., Linhart, H. G., Hadaschik, B. A., Holland-Letz, T., Giesel, F. L., Kratochwil, C., Haufe, S., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2298-2 · Cited by 915
Self-citation68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
Eder, M., Schäfer, M., Bauder-Wüst, U., Hull, W.-E., Wängler, C., Mier, W., Haberkorn, U., & Eisenhut, M. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200279b · Cited by 843
Self-citationBostwick, D. G., Pacelli, A., Blute, M., Roche, P., & Murphy, G. P. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s · Cited by 698
Sweat, S. D., Pacelli, A., Murphy, G. P., & Bostwick, D. G. (1998) · Urology · doi:10.1016/s0090-4295(98)00278-7 · Cited by 607
Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A. K., Navarro, V., Knudsen, B., & Bander, N. H. (1997) · PubMed · Cited by 528
Ross, J. S., Sheehan, C. E., Fisher, H. A. �., Kaufman, R. P., Kaur, P., Gray, K., Webb, I. J., Gray, G. S., Mosher, R. E., & Kallakury, B. (2003) · PubMed · Cited by 513
Mannweiler, S., Amersdorfer, P., Trajanoski, S., Terrett, J. A., King, D., & Mehes, G. (2009) · Pathology & Oncology Research · doi:10.1007/s12253-008-9104-2 · Cited by 384
Afshar-Oromieh, A., Haberkorn, U., Eder, M., Eisenhut, M., & Zechmann, C. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2069-0 · Cited by 325
Self-citationHillier, S. M., Maresca, K. P., Femia, F. J., Marquis, J. C., Foss, C. A., Nguyen, N., Zimmerman, C. N., Barrett, J. A., Eckelman, W. C., Pomper, M. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1682 · Cited by 316
Cimitan, M., Bortolus, R., Morassut, S., Canzonieri, V., Garbeglio, A., Baresic, T., Borsatti, E., Drigo, A., & Trovò, M. G. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0150-2 · Cited by 312
Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer
Husarik, D. B., Miralbell, R., Dubs, M., John, H., Giger, O. T., Gelet, A., Cservenyàk, T., & Hany, T. F. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0552-9 · Cited by 295
Banerjee, S. R., Foss, C. A., Castanares, M., Mease, R. C., Byun, Y., Fox, J. J., Hilton, J., Lupold, S. E., Kozikowski, A. P., & Pomper, M. G. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800111u · Cited by 233
Heinisch, M., Dirisamer, A., Loidl, W., Stoiber, F., Gruy, B., Haim, S., & Langsteger, W. (2006) · Molecular Imaging and Biology · doi:10.1007/s11307-005-0023-2 · Cited by 191
Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations
Jadvar, H. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2361-7 · Cited by 158
PSMA as a target for radiolabelled small molecules
Eder, M., Eisenhut, M., Babich, J. W., & Haberkorn, U. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2374-2 · Cited by 149
Self-citationTechnology Insight: monoclonal antibody imaging of prostate cancer
Bander, N. H. (2006) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0452 · Cited by 130
In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer
Breeuwsma, A. J., Pruim, J., Jongen, M. M., Suurmeijer, A. J. H., Vaalburg, W., Nijman, R. J. M., & de Jong, I. J. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1741-4 · Cited by 107
Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence
Steiner, C., Vees, H., Zaidi, H., Wissmeyer, M., Berrebi, O., Kossovsky, M. P., Khan, H. G., Miralbell, R., Ratib, O. M., & Buchegger, F. (2009) · Nuklearmedizin - NuclearMedicine · doi:10.3413/nukmed-0194 · Cited by 59
Beauregard, J., Williams, S., DeGrado, T. R., Roselt, P. D., & Hicks, R. J. (2010) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/j.1754-9485.2010.02178.x · Cited by 58
Kosuri, S., Akhtar, N., Smith, M. R., Osborne, J. R., & Tagawa, S. T. (2012) · Advances in Urology · doi:10.1155/2012/921674 · Cited by 40
Cited by
Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.046 · Cited by 1,079
Perera, M., Papa, N., Christidis, D., Wetherell, D., Hofman, M. S., Murphy, D. G., Bolton, D., & Lawrentschuk, N. (2016) · European Urology · doi:10.1016/j.eururo.2016.06.021 · Cited by 1,007
Eiber, M., Maurer, T., Souvatzoglou, M., Beer, A. J., Ruffani, A., Haller, B., Graner, F.-P., Kübler, H., Haberhorn, U., Eisenhut, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.154153 · Cited by 994
Self-citationAfshar-Oromieh, A., Avtzi, E., Giesel, F. L., Holland-Letz, T., Linhart, H. G., Eder, M., Eisenhut, M., Boxler, S., Hadaschik, B. A., Kratochwil, C., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2949-6 · Cited by 964
Self-citationMaurer, T., Gschwend, J. E., Rauscher, I., Souvatzoglou, M., Haller, B., Weirich, G., Wester, H.-J., Heck, M., Kübler, H., Beer, A. J., et al. (2016) · Journal of Urology · doi:10.1016/j.juro.2015.12.025 · Cited by 779
Metadata
- Authors
- Afshar-Oromieh, A., Zechmann, C. M., Malcher, A., Eder, M., Eisenhut, M., Linhart, H. G., Holland-Letz, T., Hadaschik, B. A., Giesel, F. L., Debus, J., & Haberkorn, U.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2013-09-27
- Volume
- 41
- Issue
- 1
- Pages
- 11-20
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2080006760
- Cited by
- 921
- References
- 21
- FWCI
- 62.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.